Frontlight ResearchEarly access
Active, not recruitingPhase 2/3
A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)
Key facts
- Who runs it
- Denali Therapeutics Inc.
- Where
- Chapel Hill, Chicago, Cincinnati, Hackensack, Houston, Oakland, Philadelphia, and Salt Lake City, United StatesSee the 8 sitesAlso in 13 other countries, 23 sites
- Trial code
- NCT05371613
- EU 2024-510990-21-00
- EudraCT 2021-005200-35
- ISRCTN11652897
- Status
- Active, not recruiting
- Phase
- Phase 2/3
- People taking part
- 65 people enrolled
- Started
- 21 Jul 2022
- Expected to end
- Dec 2027
- Type of study
- Interventional, 3 groups
- Treatments tested
- tividenofusp alfa
- idursulfase
- Record updated
- 9 September 2026
Who can take part
- Age
- 2 years to 25 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Participants aged ≥2 to <6 years (Cohort A) or ≥6 to <26 years (Cohort B)
- Confirmed diagnosis of MPS II (for Cohort A, nMPS II; for Cohort B, nnMPS II)
- Have no history of treatment with enzyme replacement therapy (ERT) OR not have received continuous ERT for 4 months prior to screening OR be on maintenance ERT and have tolerated idursulfase for a minimum of 4 months prior to screening
Who cannot take part
- Previously received an iduronate 2-sulfatase (IDS) gene therapy or stem cell therapy
- Received any CNS-targeted MPS ERT within 6 months prior to screening
- Participated in any other investigational drug study or used an investigational drug within 60 days prior to screening or intend to receive another investigational drug during the study
- Have a documented mutation of other genes or genetic diagnosis accounting for developmental delay
- Have a contraindication for lumbar punctures and/or magnetic resonance imaging (MRI)
Where in United States
Also in 13 other countries, 23 sites
- UNC Children's Research InstituteChapel Hill, United States
- Ann and Robert H. Lurie Children's Hospital of ChicagoChicago, United States
- Cincinnati Children's Hospital Medical CenterCincinnati, United States
- Hackensack University Medical CenterHackensack, United States
- The University of Texas Medical School at HoustonHouston, United States
- UCSF Benioff Children's Hospital OaklandOakland, United States
- Children's Hospital of PhiladelphiaPhiladelphia, United States
- University of Utah - PPDSSalt Lake City, United States
About the trial
What the trial wants to find out
This is a Phase 2/3, multiregional, two-arm, double-blind, randomized, active (standard-of-care)-controlled study of the efficacy and safety of tividenofusp alfa (DNL310), an investigational central nervous system (CNS)-penetrant enzyme-replacement therapy (ERT) for mucopolysaccharidosis type II (MPS II).
Read full original descriptionShow less
Participants may also qualify to enter an open-label treatment phase with DNL310 or idursulfase based on pre-specified criteria.
The 3 groups in the trial
- Cohort A: Participants with nMPS IITreatment being tested
Treatment: tividenofusp alfa and idursulfase
- Cohort B: Participants with nnMPS IITreatment being tested
Treatment: tividenofusp alfa and idursulfase
- Open-label Treatment PhaseTreatment being tested
Participants who meet pre-specified criteria may receive DNL310 or idursulfase
Treatment: tividenofusp alfa and idursulfase
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Phase 2/3, Multicenter, Double-Blind, Randomized Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic or Non-Neuronopathic Mucopolysaccharidosis Type II
- Record updated
- 9 September 2026